At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 160 enrolled
Drug / intervention
ACC-001 + QS-21 +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimers Disease
In Brief
A Phase 2 clinical trial evaluating ACC-001 + QS-21, QS-21, and 2 other interventions for Alzheimer Disease. Completed, enrolled 160 participants across 27 sites.
Detailed Summary
To access the safety, tolerability, and immunogenicity of ACC-001, an investigational active immunization, in subjects with mild to moderate Alzheimer's disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease
CountriesUnited States
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 2007
Enrollment StartNov 2007
Primary CompletionFeb 2013
TodayJul 2026
First PostedJul 10, 2007
Enrollment StartNov 1, 2007
Primary CompletionFeb 1, 2013
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 19.0 years ago
Interventions
ACC-001 + QS-21biological
IM injection, ACC-001 (3ug, or 10ug, or 30ug) + QS-21 50ug at Day 1 and weeks 4, 12, 26, and 52
QS-21biological
IM injection, QS-21 (50 ug) at Day 1 and weeks 4, 12, 26, and 52
Diluent: Phosphate Buffered Salineother
IM injection, PBS Diluent at Day 1 and weeks 4, 12, 26, and 52
ACC-001biological
IM injection, ACC 001 (10 ug, 30ug) at Day 1 and weeks 4, 12, 26, and 52